Recent years have brought tremendous progress in demonstrating that there is hope for improving mortality from pancreatic ductal adenocarcinoma through early detection.
Matthew B. Yurgelun, MD
Advertisement
Articles by Matthew B. Yurgelun, MD
Because specific risk-reducing interventions may be available, it is important to identify individuals with germline variants in cancer susceptibility genes.
Matthew B. Yurgelun, MD, assistant professor of Medicine, Harvard Medical School, and a researcher at the Dana-Farber Cancer Institute, discusses germline testing in colorectal cancer.
Matthew B. Yurgelun, MD, Targeted Oncology, Yurgelun, Instructor in Medicine, Harvard Medical School, discusses a recent study which uncovered BRCA1 and BRCA2 mutations as possible risk markers for colorectal cancer.
Advertisement
Latest Updated Articles
Updates on Imaging-Based Pancreatic Cancer Surveillance for Individuals With Increased Genetic and Familial RiskPublished: August 15th 2023 | Updated:
Dr. Matthew Yurgelun on Next Steps in Understanding CRC MutationsPublished: August 26th 2016 | Updated:
Dr. Matthew Yurgelun on Pathogenic Mutations in CRCPublished: September 22nd 2016 | Updated:
Dr. Yurgelun Discusses Germline Testing in CRCPublished: May 3rd 2017 | Updated:
Online Tool Estimates the Risk for Lynch SyndromePublished: February 5th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5